| Name | Title | Contact Details |
|---|
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Cynapsus Therapeutics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Galleon Pharmaceutical is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.